16 results on '"Ji Yuh Lee"'
Search Results
2. Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan
- Author
-
Jyh-Ming Liou, Yu-Jong Weng, Jiing-Chyuan Luo, Yang Th, Yu-Jen Fang, Chia-Chi Kuo, Min-Chin Chiu, Chieh-Chang Chen, Chien-Chun Yu, Ming-Shiang Wu, Mei-Jyh Chen, Ming-Jong Bair, and Ji-Yuh Lee
- Subjects
medicine.medical_specialty ,Stool sample ,Taiwan ,Gastroenterology ,Asymptomatic ,Helicobacter Infections ,03 medical and health sciences ,Helicobacter pylori Antigen ,Feces ,0302 clinical medicine ,Internal medicine ,Prevalence ,Medicine ,Humans ,Mass screening ,Breath test ,Antigens, Bacterial ,lcsh:R5-920 ,biology ,medicine.diagnostic_test ,Helicobacter pylori ,business.industry ,Gastric cancer prevention ,General Medicine ,biology.organism_classification ,bacterial infections and mycoses ,Breath Tests ,030220 oncology & carcinogenesis ,Stool antigen ,030211 gastroenterology & hepatology ,medicine.symptom ,Immunochromatography ,business ,lcsh:Medicine (General) ,Stool antigen test - Abstract
Background The updated prevalence of Helicobacter pylori (H. pylori) is lacking in Taiwan. We aimed to assess the accuracy of Vstrip® H. pylori Stool Antigen Rapid Test (Vstrip®HpSA) in the detection and surveillance of the updated prevalence of H. pylori in Taiwan. Methods A total of 347 adult subjects including 152 volunteers and 195 symptomatic patients were recruited. Stool samples were collected for detection of H. pylori using Vstrip® HpSA, ImmunoCard STAT!® HpSA and Premier Platinum HpSA® PLUS. All subjects who have completed the stool sample collections were included in the ITT analysis. The sensitivity, specificity, and accuracy of Vstrip® HpSA were calculated compared to gold standard test with 13C-Urea breath test. Results The un-adjusted prevalence of H. pylori infection was 22.5% (95% CI: 18.3–27%) in 2018. The age-standardized prevalence of H. pylori was 21.8% in asymptomatic adults in Taiwan. The sensitivity, specificity, and accuracy of the Vstrip® HpSA, and ImmunoCard STAT!® HpSA tests were 91% (95% CI: 82–96%) versus 76.9% (95% CI: 66–86%), 97% (95% CI: 94.1–98.6%) versus 97% (95% CI: 94.1–98.6%), and 95.7% (95% CI: 92–97%) versus 92.5% (95% CI: 89–95%), respectively. Conclusion The age-standardized prevalence of H. pylori infection in Taiwan was 21.8% in asymptomatic adults in 2018. The Vstrip® HpSA had equivalent performance as the ImmunoCard STAT!® HpSA, and can be used in future mass screening of H. pylori infection for gastric cancer prevention.
- Published
- 2020
3. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
- Author
-
Ji-Yuh Lee, Po-Yueh Chen, Tzu-Pin Lu, C. Y. Chang, Wen-Feng Hsu, Jaw-Town Lin, Chi-Yang Chang, Emad M. El-Omar, Yang Th, Chien-Chuan Chen, Chieh-Chang Chen, Mei-Jyh Chen, Yu-Jen Fang, Ming-Jong Bair, Jyh-Ming Liou, Eric Y. Chuang, Chi-Yi Chen, Taiwan Gastrointestinal Disease, Ming-Shiang Wu, Yao-Chun Hsu, Yen-Nien Chen, Jeng-Yih Wu, and Jiing-Chyuan Luo
- Subjects
Male ,0301 basic medicine ,Drug resistance ,Gastroenterology ,Body Mass Index ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Prevalence ,Medicine ,Metabolic Syndrome ,biology ,Drug Resistance, Microbial ,Middle Aged ,Anti-Bacterial Agents ,Infectious Diseases ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,medicine.drug ,Adult ,medicine.medical_specialty ,Lansoprazole ,Drug Administration Schedule ,Helicobacter Infections ,03 medical and health sciences ,Pharmacotherapy ,Clarithromycin ,Metronidazole ,Internal medicine ,Concomitant Therapy ,Escherichia coli ,Organometallic Compounds ,Humans ,Disease Eradication ,Aged ,Helicobacter pylori ,business.industry ,Amoxicillin ,Tetracycline ,biology.organism_classification ,Gastrointestinal Microbiome ,030104 developmental biology ,business ,Follow-Up Studies - Abstract
In first-line treatment of Helicobacter pylori, we have previously shown that the eradication frequency was 83·7% (95% CI 80·4-86·6) for triple therapy for 14 days (T14; lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily), 85·9% (82·7-88·6) for concomitant therapy for 10 days (C10; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily), and 90·4% (87·6-92·6) for bismuth quadruple therapy for 10 days (BQ10; bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day). In this follow-up study, we assess short-term and long-term effects of these therapies on the gut microbiota, antibiotic resistance, and metabolic parameters.This was a multicentre, open-label, randomised trial done at nine medical centres in Taiwan. Adult patients (20 years) with documented H pylori infection were randomly assigned (1:1:1, with block sizes of six) to receive T14, C10, or BQ10. We assessed long-term outcomes (reinfection frequency, changes in the gut microbiota, antibiotic resistance, and metabolic parameters) in patients with available data, excluding all protocol violators and those with unknown post-treatment H pylori status. Faecal samples were collected before treatment and 2 weeks, 2 months, and at least 1 year after eradication therapy. Amplification of the V3 and V4 hypervariable regions of the 16S rRNA was done followed by high-throughput sequencing. Susceptibility testing for faecal Escherichia coli and Klebsiella pneumoniae was done. This trial is complete and registered with ClinicalTrials.gov, NCT01906879.Between July 17, 2013, and April 20, 2016, 1620 participants were randomly assigned to the three treatment groups (540 [33%] per group). 1214 (75%) attended 1-year follow-up and are included in this analysis. Compared with baseline, alpha diversity was significantly reduced 2 weeks after T14 (p=0·0002), C10 (p0·0001), and BQ10 (p0·0001) treatment. Beta diversity was also significantly altered 2 weeks after T14 (p=0·0010), C10 (p=0·0001), and BQ10 (p=0·0001). Alpha diversity and beta diversity were restored at week 8 (p=0·14 and p=0·918, respectively) and 1 year (p=0·14 and p=0·918) after T14, but were not fully recovered at week 8 and after 1 year in patients treated with C10 (p=0·0001 and p=0·013 at week 8; p=0·019 and p=0·064 at 1 year) and BQ10 (p0·0001 and p=0·0002; p=0·001 and p=0·029). A transient increase at week 2 after T14 and C10 of the resistance rates of E coli to ampicillin-sulbactam (12% [15/127] to 66% [38/58] for T14, 7% [10/135] to 64% [28/44] for C10), cefazolin (13% [16/127] to 43% [25/58] for T14, 10% [13/135] to 41% [18/44] for C10), cefmetazole (8% [10/127] to 26% [15/58] for T14, 4% [5/135] to 18% [8/44] for C10), levofloxacin (8% [10/127] to 35% [20/58] for T14, 7% [10/135] to 32% [14/44] for C10), gentamicin (13% [19/146] to 47% [27/58] for T14, 15% [22/149] to 45% [20/44] for C10), and trimethoprim-sulfamethoxazole (33% [48/146] to 86% [50/58] for T14, 28% [42/148] to 86% [38/44] for C10; p0·05 in paired samples in the above analyses) returned to basal state at week 8 and after 1 year. Although bodyweight and body-mass index slightly increased, there were significant improvements in metabolic parameters, with a decrease in insulin resistance, triglycerides, and LDL and an increase in HDL. Overall, there was no significant change in the prevalence of metabolic syndrome at week 8 and 1 year after T14, C10, and BQ10.Eradication of H pylori infection has minimal disruption of the microbiota, no effect on antibiotic resistance of E coli, and some positive effects on metabolic parameters. Collectively, these results lend support to the long-term safety of H pylori eradication therapy.National Taiwan University Hospital and Ministry of Science and Technology of Taiwan.
- Published
- 2019
4. Morgagni hernia causing ileus and gastric emphysema
- Author
-
Ji-Yuh Lee and Chien-Hung Chen
- Subjects
Gastric emphysema ,Emphysema ,Medicine (General) ,medicine.medical_specialty ,Ileus ,business.industry ,General Medicine ,medicine.disease ,Surgery ,R5-920 ,medicine ,Humans ,Hernia ,Laparoscopy ,business ,Hernias, Diaphragmatic, Congenital - Published
- 2020
5. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
- Author
-
Jyh-Ming Liou, Po-Yueh Chen, Jiing-Chyuan Luo, Ji-Yuh Lee, Chieh-Chang Chen, Yu-Jen Fang, Tsung-Hua Yang, Chi-Yang Chang, Ming-Jong Bair, Mei-Jyh Chen, Yao-Chun Hsu, Wen-Feng Hsu, Chun-Chao Chang, Jaw-Town Lin, Chia-Tung Shun, Emad M. El-Omar, Ming-Shiang Wu, Yi-Chia Lee, Chun-Ying Wu, Jeng-Yih Wu, Ching-Chow Chen, Chun-Hung Lin, Yu-Ren Fang, Tsu-Yao Cheng, Ping-Huei Tseng, Han-Mo Chiu, Chien-Chun Yu, Min-Chin Chiu, Yen-Nien Chen, Wen-Hao Hu, Chu-Kuang Chou, Chi-Ming Tai, Ching-Tai Lee, Wen-Lun Wang, and Wen-Shiung Chang
- Subjects
Male ,Time Factors ,Levofloxacin ,Esomeprazole ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Clarithromycin ,Gastroenterology ,Middle Aged ,Anti-Bacterial Agents ,Treatment Outcome ,Breath Tests ,Doxycycline ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,medicine.drug ,Adult ,medicine.medical_specialty ,Genotype ,Medication history ,Clinical Decision-Making ,Taiwan ,Rapid urease test ,Drug Administration Schedule ,Helicobacter Infections ,03 medical and health sciences ,Predictive Value of Tests ,Metronidazole ,Internal medicine ,Drug Resistance, Bacterial ,medicine ,Humans ,Adverse effect ,Aged ,Bacteriological Techniques ,Intention-to-treat analysis ,Helicobacter pylori ,Hepatology ,business.industry ,Amoxicillin ,Proton Pump Inhibitors ,Tetracycline ,business - Abstract
Background & Aims We aimed to compare the efficacy of genotypic resistance–guided therapy vs empirical therapy for eradication of refractory Helicobacter pylori infection in randomized controlled trials. Methods We performed 2 multicenter, open-label trials of patients with H pylori infection (20 years or older) failed by 2 or more previous treatment regimens, from October 2012 through September 2017 in Taiwan. The patients were randomly assigned to groups given genotypic resistance–guided therapy for 14 days (n = 21 in trial 1, n = 205 in trial 2) or empirical therapy according to medication history for 14 days (n = 20 in trial 1, n = 205 in trial 2). Patients received sequential therapy containing esomeprazole and amoxicillin for the first 7 days, followed by esomeprazole and metronidazole, with levofloxacin, clarithromycin, or tetracycline (doxycycline in trial 1, tetracycline in trial 2) for another 7 days (all given twice daily) based on genotype markers of resistance determined from gastric biopsy specimens (group A) or empirical therapy according to medication history. Resistance-associated mutations in 23S ribosomal RNA or gyrase A were identified by polymerase chain reaction with direct sequencing. Eradication status was determined by 13C-urea breath test. The primary outcome was eradication rate. Results H pylori infection was eradicated in 17 of 21 (81%) patients receiving genotype resistance–guided therapy and 12 of 20 (60%) patients receiving empirical therapy (P = .181) in trial 1. This trial was terminated ahead of schedule due to the low rate of eradication in patients given doxycycline sequential therapy (15 of 26 [57.7%]). In trial 2, H pylori infection was eradicated in 160 of 205 (78%) patients receiving genotype resistance–guided therapy and 148 of 205 (72.2%) patients receiving empirical therapy (P = .170), according to intent to treat analysis. The frequencies of adverse effects and compliance did not differ significantly between groups. Conclusions Properly designed empirical therapy, based on medication history, is an acceptable alternative to genotypic resistance–guided therapy for eradication of refractory H pylori infection after consideration of accessibility, cost, and patient preference. ClinicalTrials.gov ID: NCT01725906.
- Published
- 2018
6. Computer-aided diagnosis for identifying and delineating early gastric cancers in magnifying narrow-band imaging
- Author
-
Ji-Yuh Lee, Kun-Pei Lin, Huai-Zhe Chen, Hsiu-Po Wang, Hsuan-Ting Chang, Tsung-Chun Lee, Takashi Kanesaka, and Noriya Uedo
- Subjects
Male ,Feature vector ,Concordance ,Pilot Projects ,Image processing ,Sensitivity and Specificity ,Narrow Band Imaging ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Stomach Neoplasms ,Gastroscopy ,Image Processing, Computer-Assisted ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Diagnosis, Computer-Assisted ,Early Detection of Cancer ,Aged ,Retrospective Studies ,Pixel ,business.industry ,Gastroenterology ,Pattern recognition ,Middle Aged ,Support vector machine ,Computer-aided diagnosis ,Case-Control Studies ,030220 oncology & carcinogenesis ,Predictive value of tests ,Test set ,Female ,030211 gastroenterology & hepatology ,Artificial intelligence ,business - Abstract
Background and Aims Magnifying narrow-band imaging (M-NBI) is important in the diagnosis of early gastric cancers (EGCs) but requires expertise to master. We developed a computer-aided diagnosis (CADx) system to assist endoscopists in identifying and delineating EGCs. Methods We retrospectively collected and randomly selected 66 EGC M-NBI images and 60 non-cancer M-NBI images into a training set and 61 EGC M-NBI images and 20 non-cancer M-NBI images into a test set. After preprocessing and partition, we determined 8 gray-level co-occurrence matrix (GLCM) features for each partitioned 40 × 40 pixel block and calculated a coefficient of variation of 8 GLCM feature vectors. We then trained a support vector machine (SVM Lv1 ) based on variation vectors from the training set and examined in the test set. Furthermore, we collected 2 determined P and Q GLCM feature vectors from cancerous image blocks containing irregular microvessels from the training set, and we trained another SVM (SVM Lv2 ) to delineate cancerous blocks, which were compared with expert-delineated areas for area concordance. Results The diagnostic performance revealed accuracy of 96.3%, precision (positive predictive value [PPV]) of 98.3%, recall (sensitivity) of 96.7%, and specificity of 95%, at a rate of 0.41 ± 0.01 seconds per image. The performance of area concordance, on a block basis, demonstrated accuracy of 73.8% ± 10.9%, precision (PPV) of 75.3% ± 20.9%, recall (sensitivity) of 65.5% ± 19.9%, and specificity of 80.8% ± 17.1%, at a rate of 0.49 ± 0.04 seconds per image. Conclusions This pilot study demonstrates that our CADx system has great potential in real-time diagnosis and delineation of EGCs in M-NBI images.
- Published
- 2018
7. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
- Author
-
Ding-Shinn Chen, Jia-Horng Kao, Yang Th, Chieh-Chang Chen, Jian-Jyun Yu, Chien-Hung Chen, Shih-Jer Hsu, Ji-Yuh Lee, Chia-Chi Kuo, Min-Chin Chiu, and Yu-Jen Fang
- Subjects
Adult ,Cyclopropanes ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Aminoisobutyric Acids ,Pyrrolidines ,Proline ,Sustained Virologic Response ,Lactams, Macrocyclic ,Taiwan ,Hepacivirus ,Gastroenterology ,Antiviral Agents ,03 medical and health sciences ,0302 clinical medicine ,Leucine ,Internal medicine ,Quinoxalines ,Clinical endpoint ,medicine ,Humans ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,lcsh:R5-920 ,Sulfonamides ,business.industry ,General Medicine ,Glecaprevir ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Pibrentasvir ,Regimen ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Benzimidazoles ,Drug Therapy, Combination ,Female ,Hepatic fibrosis ,Transient elastography ,business ,lcsh:Medicine (General) - Abstract
Background: Glecaprevir/pibrentasvir (GLE/PIB) is a pangenotypic direct-acting antiviral agent for the treatment of chronic hepatitis C virus (HCV) infection. Real-world data of GLE/PIB in Asian patients other than Japanese are limited. We thus investigated the effectiveness and safety profile of GLE/PIB in Taiwanese patients with chronic hepatitis C (CHC). Methods: CHC patients who received 8, 12, or 16 weeks of GLE/PIB between August and October of 2018 were consecutively enrolled. The treatment duration was determined according to drug label. The hepatic fibrosis was staged according to liver histology, transient elastography, fibrosis index based on 4 factors (FIB-4), or findings of ultrasonography/endoscopy. The primary endpoint was sustained virological response at week 12 off therapy (SVR12). The safety profiles were also assessed. Results: A total of 110 CHC patients with 51% of males were enrolled. The median age was 70 years. A majority (82%) of patients were infected with HCV genotype 2. Forty-six (42%) and 64 (58%) patients had advanced hepatic fibrosis and compensated cirrhosis, respectively. Forty-five (41%) non-cirrhotic patients were treated for 8 weeks. The overall SVR12 rates were 100%, regardless of baseline clinical characteristics. The common adverse events (AEs) were pruritus (12%), anorexia (6%), and fatigue (5%). Nine (8%) serious AEs unrelated to GLE/PIB occurred. Three (2%) patients had Grade 3 elevation of total bilirubin level. None had premature treatment termination, hepatic decompensation, or death. Conclusion: Interferon-free GLE/PIB regimen is highly effective and safe for Asian chronic hepatitis C patients with advanced hepatic fibrosis or compensated cirrhosis. Keywords: Chronic hepatitis C, Direct-acting antiviral, Glecaprevir, Pibrentasvir, Taiwan
- Published
- 2019
8. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
- Author
-
Yao-Chun Hsu, Chun-Chao Chang, Feng-Yun Tsao, Ji-Yuh Lee, Yu-Jen Fang, Cheng-Hao Tseng, Jaw-Town Lin, Ming-Shiang Wu, Chia-Tung Shun, Wen-Hsiung Chang, Yi-Chia Lee, Ming-Jong Bair, Chien-Chuan Chen, Tzeng-Ying Liu, Jyh-Ming Liou, Chun-Fu Hsieh, Chi-Yang Chang, Mei-Jyh Chen, Jeng-Yih Wu, Yang Th, Chieh-Chang Chen, Tai-Cherng Liou, and Jiing-Chyuan Luo
- Subjects
Adult ,Male ,medicine.medical_specialty ,HELICOBACTER PYLORI - TREATMENT ,Lansoprazole ,CYP2C19 ,Pharmacology ,Drug Administration Schedule ,Helicobacter Infections ,03 medical and health sciences ,0302 clinical medicine ,Clarithromycin ,Internal medicine ,Metronidazole ,medicine ,Ambulatory Care ,Humans ,Adverse effect ,Breath test ,biology ,medicine.diagnostic_test ,Helicobacter pylori ,business.industry ,Gastroenterology ,Amoxicillin ,Proton Pump Inhibitors ,biology.organism_classification ,ANTIBIOTIC THERAPY ,Anti-Bacterial Agents ,Hospitalization ,Treatment Outcome ,Breath Tests ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,Female ,Drug Monitoring ,business ,medicine.drug - Abstract
Objective Significant heterogeneity was observed in previous trials that assessed the efficacies of sequential therapy for 10 days (S10) versus triple therapy for 14 days (T14) in the first-line treatment of Helicobacter pylori. We aimed to compare the efficacy of S10 and T14 and assess the factors affecting their efficacies. Design We conducted this open-label randomised multicentre trial in eight hospitals and one community in Taiwan. 1300 adult subjects with H pylori infection naive to treatment were randomised (1:1) to receive S10 (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin and metronidazole for another 5 days) or T14 (lansoprazole, amoxicillin and clarithromycin for 14 days). All drugs were given twice daily. Successful eradication was defined as negative 13C-urea breath test at least 6 weeks after treatment. Our primary outcome was the eradication rate by intention-to-treat (ITT) and per-protocol (PP) analyses. Antibiotic resistance was determined by agar dilution test. Results The eradication rates of S10 and T14 were 87.2% (567/650, 95% CI 84.4% to 89.6%) and 85.7% (557/650, 95% CI 82.8% to 88.2%) in the ITT analysis, respectively, and were 91.6% (556/607, 95% CI 89.1% to 93.4%) and 91.0% (548/602, 95% CI 88.5% to 93.1%) in the PP analysis, respectively. There were no differences in compliance or adverse effects. The eradication rates in strains susceptible and resistant to clarithromycin were 90.7% and 62.2%, respectively, for S10, and were 91.5% and 44.4%, respectively, for T14. The efficacy of T14, but not S10, was affected by CYP2C19 polymorphism. Conclusions S10 was not superior to T14 in areas with low clarithromycin resistance. Trial registration number NCT01607918.
- Published
- 2015
9. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials
- Author
-
Chieh-Chang Chen, Jiing-Chyuan Luo, Chien-Chuan Chen, Ming-Shiang Wu, Ji-Yuh Lee, Yu-Jen Fang, Chi-Yang Chang, Jyh-Ming Liou, Ming-Jong Bair, Mei-Jyh Chen, Jaw-Town Lin, Wen-Feng Hsu, and Taiwan Gastrointestinal Disease
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,030106 microbiology ,Taiwan ,Microbial Sensitivity Tests ,Gastroenterology ,Risk Assessment ,beta-Lactam Resistance ,Agar dilution ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Pharmacotherapy ,Internal medicine ,Clarithromycin ,otorhinolaryngologic diseases ,polycyclic compounds ,Medicine ,Humans ,Pharmacology (medical) ,Treatment Failure ,Risk factor ,Aged ,Randomized Controlled Trials as Topic ,Pharmacology ,Aged, 80 and over ,biology ,Helicobacter pylori ,business.industry ,Amoxicillin ,Middle Aged ,biology.organism_classification ,Anti-Bacterial Agents ,Regimen ,Infectious Diseases ,Relative risk ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Background The impact of amoxicillin resistance on the efficacy of regimens containing amoxicillin for Helicobacter pylori eradication remains unknown. Objectives To investigate whether the efficacy of an amoxicillin-containing regimen is affected by amoxicillin resistance and to identify the optimal breakpoint for amoxicillin resistance. Methods This was a pooled analysis of five randomized trials conducted in Taiwan from 2007 to 2016. Patients who received amoxicillin-containing regimens were recruited. MICs were determined by agar dilution testing. Meta-analysis was performed to assess the risk ratio of eradication failure in amoxicillin-resistant strains compared with susceptible strains of seven different regimens. We performed further the pooled analysis and logistic regression in patients treated with clarithromycin triple therapy to identify the optimal breakpoint for amoxicillin resistance. Results A total of 2339 patients with available amoxicillin MICs were enrolled. Meta-analysis showed that the presence of amoxicillin resistance was consistently associated with increased risk of treatment failure of amoxicillin-containing regimens at different breakpoints (risk ratio: 1.41, 95% CI 1.12-1.78, P = 0.004 when the cut-off was 0.5 mg/L). The heterogeneity was low (I2 = 0%, P = 0.615). Pooled analysis also showed that amoxicillin resistance was an independent risk factor for treatment failure of clarithromycin triple therapy at different breakpoints. The best correlation was observed when the breakpoint of amoxicillin resistance was ≥0.125 mg/L (kappa coefficient 0.298), at which the resistance rate was 11.1% (110 of 990). Conclusions The efficacies of amoxicillin-containing regimens are affected by amoxicillin resistance and the optimal breakpoint MIC is ≥ 0.125 mg/L.
- Published
- 2017
10. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
- Author
-
Jyh-Ming, Liou, Chieh-Chang, Chen, Mei-Jyh, Chen, Chien-Chuan, Chen, Chi-Yang, Chang, Yu-Jen, Fang, Ji-Yuh, Lee, Shih-Jer, Hsu, Jiing-Chyuan, Luo, Wen-Hsiung, Chang, Yao-Chun, Hsu, Cheng-Hao, Tseng, Ping-Huei, Tseng, Hsiu-Po, Wang, Ueng-Cheng, Yang, Chia-Tung, Shun, Jaw-Town, Lin, Yi-Chia, Lee, Ming-Shiang, Wu, and Yu-Chi, Wang
- Subjects
Male ,Ofloxacin ,medicine.medical_specialty ,Lansoprazole ,2-Pyridinylmethylsulfinylbenzimidazoles ,Drug Administration Schedule ,Helicobacter Infections ,law.invention ,Pharmacotherapy ,Randomized controlled trial ,law ,Clarithromycin ,Metronidazole ,Internal medicine ,Drug Resistance, Bacterial ,medicine ,Humans ,Adverse effect ,Helicobacter pylori ,biology ,business.industry ,Standard treatment ,Amoxicillin ,General Medicine ,Middle Aged ,biology.organism_classification ,Anti-Bacterial Agents ,Surgery ,Number needed to treat ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Summary Background Whether sequential treatment can replace triple therapy as the standard treatment for Helicobacter pylori infection is unknown. We compared the efficacy of sequential treatment for 10 days and 14 days with triple therapy for 14 days in first-line treatment. Methods For this multicentre, open-label, randomised trial, we recruited patients (≥20 years of age) with H pylori infection from six centres in Taiwan. Using a computer-generated randomisation sequence, we randomly allocated patients (1:1:1; block sizes of six) to either sequential treatment (lansoprazole 30 mg and amoxicillin 1 g for the first 7 days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg for another 7 days; with all drugs given twice daily) for either 10 days (S-10) or 14 days (S-14), of 14 days of triple therapy (T-14; lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg for 14 days; with all drugs given twice daily). Investigators were masked to treatment allocation. Our primary outcome was the eradication rate in first-line treatment by intention-to-treat (ITT) and per-protocol (PP) analyses. This trial is registered with ClinicalTrials.gov, number NCT01042184. Findings Between Dec 28, 2009, and Sept 24, 2011, we enrolled 900 patients: 300 to each group. The eradication rate was 90·7% (95% CI 87·4–94·0; 272 of 300 patients) in the S-14 group, 87·0% (83·2–90·8; 261 of 300 patients) in the S-10 group, and 82·3% (78·0–86·6; 247 of 300 patients) in the T-14 group. Treatment efficacy was better in the S-14 group than it was in the T-14 group in both the ITT analysis (number needed to treat of 12·0 [95% CI 7·2–34·5]; p=0·003) and PP analyses (13·7 [8·3–40], p=0·003). We recorded no significant difference in the occurrence of adverse effects or in compliance between the three groups. Interpretation Our findings lend support to the use of sequential treatment as the standard first-line treatment for H pylori infection. Funding National Taiwan University Hospital and National Science Council.
- Published
- 2013
11. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
- Author
-
Jaw-Town Lin, Yu Jen Fang, Jeng Yih Wu, Tsung Hua Yang, Ming-Jong Bair, Ji Yuh Lee, Bor Shyang Sheu, Emad M. El-Omar, Ming-Shiang Wu, Jiing-Chyuan Luo, Chien Chuan Chen, Cheng Hao Tseng, Mei Jyh Chen, Wen-Hao Hu, Chieh Chang Chen, Po-Yueh Chen, Chi Yang Chang, Wen-Feng Hsu, Jyh-Ming Liou, Yao-Chun Hsu, Yen-Nien Chen, Chia-Tung Shun, Yi-Chia Lee, Chun Chao Chang, and Chi Yi Chen
- Subjects
Male ,medicine.medical_specialty ,Population ,Lansoprazole ,Taiwan ,Rapid urease test ,Gastroenterology ,Drug Administration Schedule ,Article ,Helicobacter Infections ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Internal medicine ,Clarithromycin ,Metronidazole ,Concomitant Therapy ,medicine ,Organometallic Compounds ,Humans ,Urea ,education ,education.field_of_study ,biology ,Helicobacter pylori ,business.industry ,Amoxicillin ,Proton Pump Inhibitors ,General Medicine ,Middle Aged ,Tetracycline ,biology.organism_classification ,Surgery ,Anti-Bacterial Agents ,Breath Tests ,030220 oncology & carcinogenesis ,Concomitant ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,Female ,Antacids ,business ,medicine.drug - Abstract
Summary Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori . Methods In this multicentre, open-label, randomised trial, we recruited adult patients (aged >20 years) with H pylori infection from nine medical centres in Taiwan. Patients who had at least two positive tests from the rapid urease test, histology, culture, or serology or who had a single positive 13 C-urea breath test for gastric cancer screening were eligible for enrolment. Patients were randomly assigned (1:1:1) to either concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily) for 10 days; bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day) for 10 days; or triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily) for 14 days. A computer-generated permuted block randomisation sequence with a block size of 6 was used for randomisation, and the sequence was concealed in an opaque envelope until the intervention was assigned. Investigators were masked to treatment allocation. The primary outcome was the eradication frequency of H pylori with first-line therapy assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01906879. Findings Between July 17, 2013, and April 20, 2016, 5454 patients were screened for eligibility. Of these, 1620 patients were randomly assigned in this study. The eradication frequencies were 90·4% (488/540 [95% CI 87·6–92·6]) for 10-day bismuth quadruple therapy, 85·9% (464/540 [82·7–88·6]) for 10-day concomitant therapy, and 83·7% (452/540 [80·4–86·6]) for 14-day triple therapy in the intention-to-treat analysis. 10-day bismuth quadruple therapy was superior to 14-day triple therapy (difference 6·7% [95% CI 2·7–10·7, p=0·001), but not 10-day concomitant therapy. 10-day concomitant therapy was not superior to 14-day triple therapy. The frequency of adverse events was 67% (358/533) in patients treated with 10-day bismuth quadruple therapy, 58% (309/535) in patients treated with 10-day concomitant therapy, and 47% (252/535) in patients treated with 14-day triple therapy. Interpretation Bismuth quadruple therapy is preferable to 14-day triple therapy in the first-line treatment in the face of rising prevalence of clarithromycin resistance. Concomitant therapy given for 10 days might not be optimum and a longer treatment length should be considered. Funding National Taiwan University Hospital and Ministry of Science and Technology of Taiwan.
- Published
- 2016
12. Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
- Author
-
H P Wang, Jaw-Town Lin, Shih-Jer Hsu, Ming-Lun Han, Ji Yuh Lee, Chun-Nien Chen, Ming-Shiang Wu, T T L Lin, Jyh-Ming Liou, Yu-Jen Fang, Ping-Huei Tseng, and Fu-Chang Hu
- Subjects
Male ,medicine.medical_specialty ,Epinephrine ,Peptic ,Lower risk ,Gastroenterology ,2-Pyridinylmethylsulfinylbenzimidazoles ,Helicobacter Infections ,Bolus (medicine) ,Risk Factors ,Internal medicine ,Electrocoagulation ,Secondary Prevention ,medicine ,Humans ,Vasoconstrictor Agents ,Pharmacology (medical) ,Prospective Studies ,Prospective cohort study ,Pantoprazole ,Aged ,Aged, 80 and over ,Dose-Response Relationship, Drug ,Helicobacter pylori ,Hepatology ,business.industry ,Hemostasis, Endoscopic ,Hazard ratio ,Proton Pump Inhibitors ,Middle Aged ,Surgery ,Regimen ,Peptic Ulcer Hemorrhage ,Hemostasis ,Regression Analysis ,Female ,business ,medicine.drug - Abstract
Summary Background The optimal dosage of intravenous proton pump inhibitors (PPIs) for the prevention of peptic ulcer rebleeding remains unclear. Aim To compare the rebleeding rate of high-dose and standard-dose PPI use after endoscopic haemostasis. Methods A total of 201 patients with bleeding ulcers undergoing endoscopic treatment with epinephrine injection and heater probe thermocoagulation were randomised to receive a high-dose regimen (80 mg bolus, followed by pantoprazole 8 mg/h infusion, n = 100) or a standard-dose regimen (pantoprazole 40 mg bolus daily, n = 101). After 72 h, all patients were given 40 mg pantoprazole daily orally for 27 days. Results There were no statistical differences in mean units of blood transfused, length of hospitalisation ≦5 days, surgical or radiological interventions and mortality within 30 days between two groups. Bleeding recurred within 30 days in six patients [6.2%, 95% confidence interval (CI) 1.3–11.1%] in the high-dose group, as compared to five patients (5.2%, 95% CI 0.6–9.7%) in the standard-dose group (P = 0.77). The stepwise Cox regression analysis showed end-stage renal disease, haematemesis, chronic obstructive pulmonary disease (hazard ratio: 37.15, 10.07, 9.12, 95% CI: 6.76–204.14, 2.07–49.01, 1.66–50.00 respectively) were independent risk factors for rebleeding and Helicobacter pylori infection was associated with lower risk of rebleeding (hazard ratio: 0.20, 95% CI: 0.04–0.94). Conclusions Following combined endoscopic haemostasis of bleeding ulcers, co-morbidities, haematemesis and H. pylori Status, but not PPI dosage, are associated with rebleeding (http://www.Clinical Trials.gov.ID: NCT00709046).
- Published
- 2012
13. Computer-generated surface and tone enhancements to distinguish neoplastic from non-neoplastic colon polyps less than 1 cm in diameter
- Author
-
Ming-Shiang Wu, T T L Lin, Yu-Jen Fang, Ji-Yuh Lee, Ping-Huei Tseng, Ming-Lun Han, Long-Wei Lin, Yi-Chia Lee, Chieh-Chang Chen, and Hsiu-Po Wang
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Non neoplastic ,Colonic Polyps ,Magnification ,Sensitivity and Specificity ,Confidence Intervals ,medicine ,Humans ,Aged ,Aged, 80 and over ,Observer Variation ,business.industry ,fungi ,Gastroenterology ,Reproducibility of Results ,food and beverages ,Histology ,Colonoscopy ,Middle Aged ,Image Enhancement ,medicine.disease ,digestive system diseases ,Colon polyps ,Colonic lesion ,Female ,business - Abstract
Computer-generated enhancements, which can highlight the surface and color of a colonic lesion, may be helpful to predict the histology; however, it remains unclear whether this technology can distinguish neoplastic from non-neoplastic colon polyps when the polyps are1 cm without magnification.Images of colorectal polyps less than 1 cm in diameter were obtained from 54 patients who underwent non-magnified colonoscopy with surface enhancement (SE) and tone enhancement (TE). We calculated the sensitivity, specificity, and accuracy in the prediction of histology. Inter- and intra-observer consistency was evaluated by inviting four endoscopists to rate 45 static images.Overall sensitivity, specificity, and accuracy following the sequence of SE, TE colon, and TE pit pattern modes were 87.7% (95% confidence interval 81.3-94.1%), 84.1% (76.9-91.3%), and 86.1% (79.4-92.8%), respectively. For each modality, the results were 75.0% (68.7-81.3%), 82.7% (77.2-88.2%), and 77.2% (71.1-83.3%) for SE; 71.1% (64.5-77.7%), 78.8 (72.8-84.8), and 73.3% (66.8-79.8%) for TE colon mode; and 75.0% (68.7-81.3%), 80.8% (75.0-86.8%), and 76.7% (70.5-82.9%) for TE pit pattern mode. Their inter- and intra-observer agreements were all fair (κ range 0.522-0.568) and good (0.605-0.694), respectively. When the same rater evaluated the same lesion under different modalities, eight of 45 (18%) polyps yielded discordant interpretations, and the possibility of incorrect diagnoses was the highest with the TE colon mode.Computer-generated enhancements are satisfactory in predicting the histology of small colon polyps without the need for magnification. This advantage is mostly related to the pit pattern enhancement.
- Published
- 2011
14. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study
- Author
-
Ji-Yuh Lee, Taiwan Gastrointestinal Disease, Jeng-Yih Wu, Yu-Jen Fang, Chun-Chao Chang, Chun Ying Wu, Jiing-Chyuan Luo, Cheng-Hao Tseng, Yang Th, Jaw-Town Lin, Ming-Shiang Wu, Bor Shyang Sheu, Mei-Jyh Chen, Tai-Cherng Liou, Wen-Hsiung Chang, Chi-Yang Chang, Jyh-Ming Liou, Chieh-Chang Chen, Ming-Jong Bair, and Hsiu-Po Wang
- Subjects
Male ,medicine.medical_specialty ,Genotype ,Virulence Factors ,Taiwan ,lcsh:Medicine ,Drug resistance ,Microbiology ,Helicobacter Infections ,Antibiotic resistance ,Levofloxacin ,Internal medicine ,Clarithromycin ,Metronidazole ,Medicine ,CagA ,Humans ,lcsh:Science ,Multidisciplinary ,biology ,Helicobacter pylori ,business.industry ,lcsh:R ,Amoxicillin ,Tetracycline ,biology.organism_classification ,Anti-Bacterial Agents ,Female ,lcsh:Q ,business ,medicine.drug ,Research Article - Abstract
Objective The Taiwan Government issued a policy to restrict antimicrobial usage since 2001. We aimed to assess the changes in the antibiotic consumption and the primary resistance of H. pylori after this policy and the impact of virulence factors on resistance. Methods The defined daily dose (DDD) of antibiotics was analyzed using the Taiwan National Health Insurance (NHI) research database. H. pylori strains isolated from treatment naive (N=1395) and failure from prior eradication therapies (N=360) from 9 hospitals between 2000 and 2012 were used for analysis. The minimum inhibitory concentration was determined by agar dilution test. Genotyping for CagA and VacA was determined by PCR method. Results The DDD per 1000 persons per day of macrolides reduced from 1.12 in 1997 to 0.19 in 2008, whereas that of fluoroquinolones increased from 0.12 in 1997 to 0.35 in 2008. The primary resistance of amoxicillin, clarithromycin, metronidazole, and tetracycline remained as low as 2.2%, 7.9%, 23.7%, and 1.9% respectively. However, the primary levofloxacin resistance rose from 4.9% in 2000–2007 to 8.3% in 2008–2010 and 13.4% in 2011–2012 (p=0.001). The primary resistance of metronidazole was higher in females than males (33.1% vs. 18.8%, p
- Published
- 2015
15. Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
- Author
-
Chia-Tung Shun, Ming-Shiang Wu, Jiing-Chyuan Luo, Chien-Chuan Chen, Wen-Hsiung Chang, Ji-Yuh Lee, Hsiu-Po Wang, Yu-Jen Fang, Jeng-Yi Wu, Chieh-Chang Chen, Mei-Jyh Chen, Ping-Huei Tseng, Yao-Chun Hsu, Yang Th, Chi-Yang Chang, Jaw-Town Lin, and Jyh-Ming Liou
- Subjects
Male ,medicine.medical_specialty ,Genotype ,Gastroenterology ,Endoscopy, Gastrointestinal ,Helicobacter Infections ,Diagnosis, Differential ,Bacterial Proteins ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,Surveys and Questionnaires ,Medicine ,CagA ,Humans ,Prospective Studies ,Dyspepsia ,Prospective cohort study ,Life Style ,Depression (differential diagnoses) ,Aged ,Sleep disorder ,Antigens, Bacterial ,biology ,Helicobacter pylori ,business.industry ,Stomach ,Overlap syndrome ,Middle Aged ,biology.organism_classification ,medicine.disease ,Postprandial Period ,Gastric Mucosa ,Concomitant ,Predictive value of tests ,Female ,business ,Stress, Psychological ,Follow-Up Studies - Abstract
Background and objective Whether there is distinct pathogenesis in subgroups of functional dyspepsia (FD), the postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) remains controversial. We aimed to identify the risk factors of FD and its subgroups in the Chinese population. Methods Patients with dyspepsia and healthy subjects who underwent gastric cancer screening were enrolled in this multicentre study from 2010 to 2012. All patients were evaluated by questionnaire, oesophagoduodenoscopy, histological examination and Helicobacter pylori tests. Subgroups of FD were classified according to the Rome III criteria. Psychiatric stress was assessed by the short form Brief Symptom Rating Scale. CagA and VacA genotypes were determined by PCR. Results Of 2378 patients screened for eligibility, 771 and 491 fulfilled the diagnostic criteria of uninvestigated dyspepsia and FD, respectively. 298 (60.7%) and 353 (71.9%) individuals were diagnosed with EPS and PDS, respectively, whereas 169 (34.4%) had the overlap syndrome. As compared with 1031 healthy controls, PDS and EPS shared some common risk factors, including younger age (OR 0.95; 99.5% CI 0.93 to 0.98), non-steroidal anti-inflammatory drugs (OR 6.60; 99.5% CI 3.13 to 13.90), anxiety (OR 3.41; 99.5% CI 2.01 to 5.77) and concomitant IBS (OR 6.89; 99.5% CI 3.41 to 13.94). By contrast, H. pylori (OR 1.86; 99.5% CI 1.01 to 3.45), unmarried status (OR 4.22; 99.5% CI 2.02 to 8.81), sleep disturbance (OR 2.56; 99.5% CI 1.29 to 5.07) and depression (OR 2.34; 99.5% CI 1.04 to 5.36) were associated with PDS. Moderate to severe antral atrophy and CagA positive strains were also more prevalent in PDS. Conclusions Different risk factors exist among FD subgroups based on the Rome III criteria, indicating distinct aetiopathogenesis of the subdivisions that may necessitate different therapeutic strategies.
- Published
- 2014
16. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial
- Author
-
Jyh-Ming, Liou, Chieh-Chang, Chen, Chi-Yang, Chang, Mei-Jyh, Chen, Yu-Jen, Fang, Ji-Yuh, Lee, Chien-Chuan, Chen, Shih-Jer, Hsu, Yao-Chun, Hsu, Cheng-Hao, Tseng, Ping-Huei, Tseng, Lawrence, Chang, Wen-Hsiung, Chang, Hsiu-Po, Wang, Chia-Tung, Shun, Jeng-Yih, Wu, Yi-Chia, Lee, Jaw-Town, Lin, Ming-Shiang, Wu, and Yu-Chi, Wang
- Subjects
Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,Genotype ,medicine.drug_class ,Tetracycline ,Antibiotics ,Microbial Sensitivity Tests ,Biology ,Gastroenterology ,Polymerase Chain Reaction ,Helicobacter Infections ,Levofloxacin ,Clarithromycin ,Internal medicine ,Drug Resistance, Bacterial ,medicine ,Humans ,Urea ,Pharmacology (medical) ,Prospective Studies ,Aged ,Pharmacology ,Intention-to-treat analysis ,Helicobacter pylori ,Sequence Analysis, DNA ,Amoxicillin ,Middle Aged ,biology.organism_classification ,Surgery ,Anti-Bacterial Agents ,Metronidazole ,Infectious Diseases ,Treatment Outcome ,Breath Tests ,Female ,Drug Monitoring ,medicine.drug - Abstract
The efficacy of sequential therapy and the applicability of genotypic resistance to guide the selection of antibiotics in the third-line treatment of Helicobacter pylori have not been reported. We aimed to assess the efficacy of genotypic resistance-guided sequential therapy in third-line treatment.Genotypic and phenotypic resistances were determined in patients who failed at least two eradication therapies by PCR with direct sequencing and agar dilution test, respectively. The patients were retreated with sequential therapy containing esomeprazole and amoxicillin for the first 7 days, followed by esomeprazole and metronidazole plus clarithromycin, levofloxacin or tetracycline for another 7 days (all twice daily), according to genotypic resistance determined using gastric biopsy specimens. Eradication status was determined by the (13)C-urea breath test. Trial registered at clinicaltrials.gov (identifier: NCT01032655).The overall eradication rate was 80.7% (109/135, 95% CI 73.3%-86.5%) in the intention-to-treat analysis. The presence of amoxicillin resistance (OR 6.83, 95% CI 1.62-28.86, P = 0.009) and prior sequential therapy (OR 4.77, 95% CI 1.315-17.3, P = 0.017), but not tetracycline resistance (tetracycline group), were associated with treatment failure. The eradication rates in patients who received clarithromycin-, levofloxacin- and tetracycline-based sequential therapies were 78.9% (15/19), 92.2% (47/51) and 71.4% (25/35) in strains susceptible to clarithromycin, levofloxacin and tetracycline, respectively.A simple molecular method guiding sequential therapy can achieve a high eradication rate in the third-line treatment of refractory H. pylori infection.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.